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Introduction: With the introduction of photosensitizing drugs
allowing photodynamic diagnostic (PDD) for the bladder
cancer, diagnosis has become more accurate. The main
limitation of the procedure is the false-positive detection rate,
which ranges from 12% to 60%. The onset of multifocal
transitional cell carcinoma has been described as a panurothelial
disease as it evolves because of genetic defects that are present
also in histological negative urothelial tissue. Objective: We
analyzed chromosomal patterns of false-positive lesions in the
PDD and compared them with the findings of random biopsies
with the intent to observe if hexaminolevulinate detects
chromosomal aberrations in histological healthy tissue. Patients
and Methods: Included in the study were 18 patient,16 men and
2 women, with a mean age of 70.5 (range=47-83) years. All had
false-positive PDD confirmed in the histology. A random
sample was taken from all patients. The chromosomal patterns
of all samples were analyzed with fluorescence in situ
hybridization (FISH). Results: From January 2012 until
November 2014, a total of 266 bladder biopsies were performed
in 30 patients with a positive PDD finding. Eighteen patients
had false-positive biopsies in a total of 40 biopsies. In these
patients, a total of 25 random biopsies were also performed.
Seven out of 18 patients showed chromosomal aberration in 10
(25%) of the false-positive biopsies. All 10 biopsies showed
aneusomy of the Locus 9p21 (p16), 6 (13%) aneusomy of
chromosome 3 and 5 biopsies (12,5%) aneusomy of
chromosome 7 and chromosome 17. In 4 patients, the FISH of
the control random biopsy was positive. One had an aneusomy
of Locus 9p21 (p16), the other three had anuesomy also for
chromosomes 3, 7 and 17. Conclusion: In our trial, over a third
of the patients with a false-positive PDD finding already express
chromosomal aberrations in these lesions.
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Aim: To assess perioperative, functional and oncological
results of simple enucleation (SE) in patients with highly
complex renal tumors (PADUA score 10-13). Materials and
Methods: Data of 510 patients treated with SE for renal cell
carcinoma (RCC) between July 2006 and August 2013 in our
Department were gathered in a prospectively maintained
database. Of these, 96 had highly complex renal tumors
(PADUA 10-13, Figure 1A) and were selected for this study,
including 76 treated open and 20 with robotic SE
(endoscopic robotic-assisted simple enucleation (ERASE)).
Conventional perioperative variables were collected and
compared between open and robotic approach with univariate
analysis. Survival status and functional data were gathered
at follow-up. The probability of survival was estimated by
the Kaplan-Meier method. Results: Mean (range) clinical
tumor diameter was 4.8 cm (interquartile range (IQR)=3-10).
PADUA score was 10, 11, 12 and 13 in 57.3%, 29.2%,
11.5% and 2.1% of tumors, respectively. Overall, 19.8% of
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patients had stage ≥3 chronic kidney disease (CKD) and
17.7% an imperative/relative indication. Clamping of renal
pedicle was used for almost all patients (99%) with a mean
warm ischemia time (WIT) of 19.2±5.7 minutes. Mean
operative time was 126 minutes, mean estimated blood loss
(EBL) 200 cc and median length of stay (LOS) 6 days
(IQR=5-7). Percentage of patients with postoperative
complications was 26.1% (2.1% Clavien 1, 14.6% Clavien
2, 8.3% Clavien 3, 1% Clavien 4). Benign tumors accounted
for 12.5% of patients. Positive surgical margin (PSM) rate
was 3.6% (3/84). The trifecta outcome was accomplished in
56.2% of patients. The mean±SD (range) follow-up was
54±26 (14-96) months. The 5-year cancer-specific survival
(CSS), recurrence-free survival (RFS) and overall survival
(OS) rates resulted 96.1%, 90.8% and 88.0%, respectively.
Preoperative, 3rd postoperative day, one month postoperative
and follow-up median (IQR) estimated glomerular filtration
rate (eGFR) was 79 (64-97), 68 (51-82), 76 (56-88) and 66
(50-81) ml/min/1.73 m2, respectively (Figure 1B).
Discussion and Conclusion: The optimal oncological and
functional results of SE suggest that ERASE is particularly
appropriate to treat highly complex renal masses, minimizing
the loss of healthy renal volume and widening the indications
of NSS according to the latest European Association of
Urology (EAU) guidelines.
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Introduction and Objectives: Operator-dependency and lack
of standardized diagnostic criteria may affect ability of high
grade prostatic intraepithelial neoplasia (HGPIN) and
atypical small acinar proliferation (ASAP) to predict prostate
cancer (PCa). We assessed the long-term predictive ability of
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